Comparative Pharmacology
Head-to-head clinical analysis: SULFA TRIPLE 2 versus SULFACEL 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFA TRIPLE 2 versus SULFACEL 15.
SULFA-TRIPLE #2 vs SULFACEL-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The sulfonamides (sulfamethazine, sulfathiazole, sulfamerazine) act as competitive inhibitors of para-aminobenzoic acid (PABA) utilization in bacterial dihydrofolate synthesis, thereby inhibiting folic acid synthesis and bacterial growth.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
2 tablets orally every 4 hours initially, then 2 tablets every 6 hours thereafter. Each tablet contains 167 mg sulfadiazine, 167 mg sulfamerazine, and 167 mg sulfamethazine (total sulfonamide 500 mg per tablet).
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
None Documented
None Documented
Sulfadiazine: 10-16 hours; Sulfamerazine: 15-24 hours; Sulfamethazine: 12-24 hours. The combined half-life is approximately 15-20 hours in patients with normal renal function, requiring dosing every 12-24 hours.
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
Renal (approximately 70-80% as unchanged sulfonamides via glomerular filtration and tubular secretion); biliary/fecal (approximately 20-30% as metabolites).
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)